Welcome to our dedicated page for KESTRA MED TECHNOLOGIES SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited report beneficial ownership of 2,448,942 Kestra Medical Technologies common shares, representing 4.20% of the class.
The filing explains that 2,405,643 shares are held by Endeavour Medtech Growth II LP and 43,299 shares by Endeavour Medtech Growth II Parallel LP, with Endeavour Medtech II GP Limited as general partner for both. All reported shares are subject to shared voting and dispositive power, with no sole voting or dispositive authority. The 4.20% figure is based on 58,349,053 common shares outstanding as of December 5, 2025.
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting a significant passive ownership position in Kestra Medical Technologies common stock. As of 12/31/2025, it reported beneficial ownership of 4,369,429 shares, representing 7.5% of the outstanding common stock.
The firm reports sole voting power over 4,208,056 shares and sole dispositive power over all 4,369,429 shares, with no shared voting or dispositive power. T. Rowe Price certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Kestra, and expressly denies beneficial ownership in a legal-admission sense.
Kestra Medical Technologies president, chief executive officer and director Brian Daniel Webster reported selling 15,000 common shares of KMTS on January 15, 2026. The sale was coded as an open-market sale and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance. The shares were sold at a weighted average price of $22.8016, with individual sale prices ranging from $22.2800 to $23.1340. After this transaction, Webster beneficially owns 394,786 common shares, held directly.
This Form 144 notice reports a planned sale of restricted common shares of Kestra Medical Technologies, Ltd. The seller intends to sell 15,000 common shares through Merrill Lynch on the NASDAQ, with an indicated aggregate market value of $342,023.69. The shares form part of a larger base of 58,349,053 common shares outstanding.
The securities were originally acquired on 03/07/2025 as a restricted share issuance from Kestra Medical Technologies, Ltd., granted under the issuer’s equity compensation plan. The notice also shows that Brian Webster sold 15,000 common shares on 12/29/2025 for gross proceeds of $398,847.04. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the company.
Kestra Medical Technologies, Ltd. filed a current report stating that it issued a press release announcing its financial results for the fiscal quarter ended October 31, 2025.
The press release, dated December 11, 2025, is attached as Exhibit 99.1, is incorporated by reference into this report, and is furnished rather than filed, so it is not automatically incorporated into other securities filings unless specifically referenced.
Kestra Medical Technologies (KMTS) disclosed an initial ownership filing on Form 3 for officer Timothy P. Moran, who serves as Chief Business Officer. The filing states “No securities are beneficially owned.” The date of event is 11/03/2025. This is an administrative disclosure under Section 16 reporting Mr. Moran’s starting beneficial ownership status with the company.
Kestra Medical Technologies (KMTS) filed an 8‑K under Regulation FD, furnishing a press release titled “Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device.” The release announces primary results from the ACE‑PAS post‑approval study, presented as late‑breaking science at the American Heart Association Scientific Sessions 2025 in New Orleans.
The press release is furnished as Exhibit 99.1 and, as noted, is not deemed “filed” for Section 18 liability purposes or incorporated by reference unless specifically stated. The filing includes customary forward‑looking statements language and directs readers to risk factors in the company’s Form 10‑K for the fiscal year ended April 30, 2025.
FMR LLC and Abigail P. Johnson reported beneficial ownership of 5,225,988 shares of Kestra Medical Technologies Inc. common stock, representing 10.2% of the class as of the event date 09/30/2025. The filing shows FMR LLC holds 5,225,753 shares with sole voting power and 5,225,988 shares with sole dispositive power; Abigail P. Johnson is reported with sole dispositive power over the same 5,225,988 shares. The statement is filed on Schedule 13G (Amendment No. 1), indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures indicate filings were executed on 10/06/2025 and reference powers of attorney attached to earlier Schedule 13G filings.
Amended Form 4 for Alfred J. Ford Jr. at Kestra Medical Technologies (KMTS). The filing retroactively reports the purchase of 20,000 common shares on 03/07/2025 at a price of $17.00 per share, acquired under the issuer's initial public offering reserved share program. Following this transaction, the reporting person beneficially owns 49,412 common shares in a direct capacity. The amendment states the shares were inadvertently omitted from prior filings. The form is signed by an attorney-in-fact for the reporting person.
Amended Form 4 for Alfred J. Ford Jr. at Kestra Medical Technologies (KMTS). The filing retroactively reports the purchase of 20,000 common shares on 03/07/2025 at a price of $17.00 per share, acquired under the issuer's initial public offering reserved share program. Following this transaction, the reporting person beneficially owns 49,412 common shares in a direct capacity. The amendment states the shares were inadvertently omitted from prior filings. The form is signed by an attorney-in-fact for the reporting person.
Traci S. Umberger, General Counsel and Chief Administrative Officer and a director, reported an amended Form 4 correcting prior filings to show purchase of 13,500 common shares of Kestra Medical Technologies, Ltd. The transaction occurred on 03/07/2025 at $17.00 per share under the issuer's initial public offering reserved share program. Following the reported purchase, Umberger beneficially owned 134,336 common shares, held directly. The amendment states the shares were inadvertently omitted from prior filings and are now disclosed.